Literature DB >> 25142300

IL-15-dependent CD8+ CD122+ T cells ameliorate experimental autoimmune encephalomyelitis by modulating IL-17 production by CD4+ T cells.

Ping Yu1, Richard N Bamford, Thomas A Waldmann.   

Abstract

Interleukin-15 (IL-15) is an inflammatory cytokine whose role in autoimmune diseases has not been fully elucidated. Th17 cells have been shown to play critical roles in experimental autoimmune encephalomyelitis (EAE) models. In this study, we demonstrate that blockade of IL-15 signaling by TMβ-1 mAb treatment aggravated EAE severity. The key mechanism was not NK-cell depletion but depletion of CD8+ CD122+ T cells. Adoptive transfer of exogenous CD8+ CD122+ T cells to TMβ-1-treated mice rescued animals from severe disease. Moreover, transfer of preactivated CD8+ CD122+ T cells prevented EAE development and significantly reduced IL-17 secretion. Naïve effector CD4+ CD25- T cells cultured with either CD8+ CD122+ T cells from wild-type mice or IL-15 transgenic mice displayed lower frequencies of IL-17A production with lower amounts of IL-17 in the supernatants when compared with production by effector CD4+ CD25- T cells cultured alone. Addition of a neutralizing antibody to IL-10 led to recovery of IL-17A production in Th17 cultures. Furthermore, coculture of CD8+ CD122+ T cells with effector CD4+ T cells inhibited their proliferation significantly, suggesting a regulatory function for IL-15 dependent CD8+ CD122+ T cells. Taken together, these observations suggest that IL-15, acting through CD8+ CD122+ T cells, has a negative regulatory role in reducing IL-17 production and Th17-mediated EAE inflammation.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD8+CD122+ T cells; Experimental autoimmune encephalomyelitis; Interleukin-15; Interleukin-17; Multiple sclerosis

Mesh:

Substances:

Year:  2014        PMID: 25142300      PMCID: PMC7720079          DOI: 10.1002/eji.201444675

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  50 in total

1.  Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells.

Authors:  Agustina Tri Endharti; Muhaimin Rifa'I; Zhe Shi; Yukari Fukuoka; Yoshio Nakahara; Yoshiyuki Kawamoto; Kozue Takeda; Ken-Ichi Isobe; Haruhiko Suzuki
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

2.  Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity.

Authors:  Y S Kim; W Maslinski; X X Zheng; A C Stevens; X C Li; G H Tesch; V R Kelley; T B Strom
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

3.  CD8+ T regulatory cells express the Ly49 Class I MHC receptor and are defective in autoimmune prone B6-Yaa mice.

Authors:  Hye-Jung Kim; Xuan Wang; Soroosh Radfar; Thomas J Sproule; Derry C Roopenian; Harvey Cantor
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-13       Impact factor: 11.205

4.  Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice.

Authors:  Ashutosh K Mangalam; David Luckey; Shailendra Giri; Michele Smart; Larry R Pease; Moses Rodriguez; Chella S David
Journal:  J Autoimmun       Date:  2012-03-28       Impact factor: 7.094

5.  Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease.

Authors:  Mélika Benahmed; Bertrand Meresse; Bertrand Arnulf; Ullah Barbe; Jean-Jacques Mention; Virginie Verkarre; Matthieu Allez; Christophe Cellier; Olivier Hermine; Nadine Cerf-Bensussan
Journal:  Gastroenterology       Date:  2006-12-16       Impact factor: 22.682

6.  Preclinical and phase I clinical trial of blockade of IL-15 using Mikbeta1 monoclonal antibody in T cell large granular lymphocyte leukemia.

Authors:  John C Morris; John E Janik; Jeffrey D White; Thomas A Fleisher; Margaret Brown; Mitsuru Tsudo; Carolyn K Goldman; Bonita Bryant; Michael Petrus; Lois Top; Cathryn C Lee; Wendy Gao; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-30       Impact factor: 11.205

7.  IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.

Authors:  J Marks-Konczalik; S Dubois; J M Losi; H Sabzevari; N Yamada; L Feigenbaum; T A Waldmann; Y Tagaya
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 8.  The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design.

Authors:  Thomas A Waldmann
Journal:  Nat Rev Immunol       Date:  2006-08       Impact factor: 53.106

9.  Murine CD8+ T cells that specifically delete autologous CD4+ T cells expressing V beta 8 TCR: a role of the Qa-1 molecule.

Authors:  H Jiang; R Ware; A Stall; L Flaherty; L Chess; B Pernis
Journal:  Immunity       Date:  1995-02       Impact factor: 31.745

10.  Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia.

Authors:  Thomas A Waldmann; Kevin C Conlon; Donn M Stewart; TatYana A Worthy; John E Janik; Thomas A Fleisher; Paul S Albert; William D Figg; Shawn D Spencer; Mark Raffeld; Jean R Decker; Carolyn K Goldman; Bonita R Bryant; Michael N Petrus; Stephen P Creekmore; John C Morris
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

View more
  28 in total

Review 1.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

2.  IL-15 receptor α signaling constrains the development of IL-17-producing γδ T cells.

Authors:  Sara L Colpitts; Lynn Puddington; Leo Lefrançois
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-20       Impact factor: 11.205

3.  Regulatory T cells limit unconventional memory to preserve the capacity to mount protective CD8 memory responses to pathogens.

Authors:  Andreia S Da Costa; Jessica B Graham; Jessica L Swarts; Jennifer M Lund
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-29       Impact factor: 11.205

4.  CD4 effector T cell differentiation is controlled by IL-15 that is expressed and presented in trans.

Authors:  Adam T Waickman; Davinna L Ligons; SuJin Hwang; Joo-Young Park; Vanja Lazarevic; Noriko Sato; Changwan Hong; Jung-Hyun Park
Journal:  Cytokine       Date:  2017-08-12       Impact factor: 3.861

5.  Regulation of Diabetogenic Immunity by IL-15-Activated Regulatory CD8 T Cells in Type 1 Diabetes.

Authors:  Blair T Stocks; Christopher S Wilson; Andrew F Marshall; Emilee M Hoopes; Daniel J Moore
Journal:  J Immunol       Date:  2019-05-24       Impact factor: 5.422

6.  IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses.

Authors:  Rosa M Santana Carrero; Figen Beceren-Braun; Sarai C Rivas; Shweta M Hegde; Achintyan Gangadharan; Devin Plote; Gabriel Pham; Scott M Anthony; Kimberly S Schluns
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-26       Impact factor: 11.205

Review 7.  Multiple Sclerosis and T Lymphocytes: An Entangled Story.

Authors:  Laurine Legroux; Nathalie Arbour
Journal:  J Neuroimmune Pharmacol       Date:  2015-05-07       Impact factor: 4.147

Review 8.  The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.

Authors:  Rui Li; Amit Bar-Or
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

9.  Immune Autoregulatory CD8 T Cells Require IFN-γ Responsiveness to Optimally Suppress Central Nervous System Autoimmunity.

Authors:  Alexander W Boyden; Ashley A Brate; Laura M Stephens; Nitin J Karandikar
Journal:  J Immunol       Date:  2020-06-12       Impact factor: 5.422

10.  Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo.

Authors:  Jillian M Richmond; James P Strassner; Lucio Zapata; Madhuri Garg; Rebecca L Riding; Maggi A Refat; Xueli Fan; Vincent Azzolino; Andrea Tovar-Garza; Naoya Tsurushita; Amit G Pandya; J Yun Tso; John E Harris
Journal:  Sci Transl Med       Date:  2018-07-18       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.